InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,509.01
(
0.62%
)
US TECH 100
19,460.00
(
0.95%
)
Dow Jones
39,331.85
(
0.41%
)
Brent Oil
86.57
(
0.14%
)
Bitcoin
60,963.24
(
-1.71%
)
Post# of 567
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

peewee

Send PM Follow Ignore
Followers 116
Posts 33453
Boards Moderated 3
Alias Born 10/22/2007

peewee

Re: peewee post# 506

Friday, 06/04/2010 6:55:02 AM

Friday, June 04, 2010 6:55:02 AM

Post# of 567
FDAnews Drug Daily Bulletin
June 4, 2010 | Vol. 7 No. 109

Antisoma’s AS1413 Gains FDA Fast Track Status for Myeloid Leukemia
Cancer drug developer Antisoma Thursday announced that the FDA has granted Fast Track designation to the Company’s novel DNA intercalator, AS1413 (amonafide L-malate), for the treatment of secondary acute myeloid leukemia.



http://www.fdanews.com/newsletter/...sueId=13751&articleId=127580

Antisoma IHUB board:
http://investorshub.advfn.com/boards/board.aspx?board_id=17986


Longterm Investment, Biotechs & High Yield Dividend Stocks ... #board-11828

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up